Cancer 2025: Group photo at Singapore

 🌟 Celebrating an Inspiring Gathering of Global Visionaries! 🌟

We are delighted to showcase this memorable group photo from the International Conference on Cancer Science and Research, hosted in Singapore from November 17–19, 2025.

This moment reflects a vibrant assembly of:

✨ Renowned Keynote Speakers

✨ Impactful Oral Presenters

✨ Creative Poster Presenters

✨ Dedicated researchers, medical professionals, and scientific leaders

Together, these delegates fostered an atmosphere of shared knowledge, innovative discussion, and meaningful connections — all driven by the collective goal of advancing breakthroughs in cancer science.

Our heartfelt appreciation goes out to every individual who took part, exchanged knowledge, and brought energy and excellence to the event. Because of you, the conference was not only successful — it was truly inspiring. 🙌🧬💫

Learn more about our distinguished speakers here: https://cancer.miconferences.com/speakers/2025

#CancerScience2025 #CancerResearch #SingaporeConference #ScientificInnovation #KeynoteSpeakers #GlobalExperts #PosterPresentation #OralPresentation #CollaborationInScience

Cancer 2025: Pre-Conference Dinner on November 16, 2025

✨ A Remarkable Start to an Inspiring Conference! ✨

Our Pre-Conference Dinner on November 16, 2025, in Singapore was a delightful prelude to the International Conference on Cancer Science & Research.

Bringing together distinguished Keynote Speakers, Moderators, Delegates, and brilliant Researchers, the evening offered an engaging blend of professional connection and personal warmth.

Highlights of the night included:

🌟 Engaging introductions across specialties
🗨 Thought-provoking discussions on cutting-edge cancer research
🌐 Building new international alliances
🥂 A friendly and relaxed atmosphere
🎯 A spirit of collaboration and forward-thinking exploration

We extend our heartfelt thanks to every participant for contributing to such a dynamic and uplifting evening. Your enthusiasm and presence energized the conference that followed.

Here’s to meaningful exchanges, impactful discoveries, and many more enriching gatherings ahead!

To join us for further events, visit our conference website: https://cancer.miconferences.com/

#CancerScience #OncologyCommunity #NetworkingDinner #GlobalCollaboration #ScientificExchange #Singapore2025 #MathewsInternational

@sergey19571989 @BenJonatha21486 @NCKU_official @uofcincy

🔵 Breakthrough Research: Blocking the Prolactin Receptor to Suppress Breast Cancer

Speaker: Nira Ben Jonathan, University of Cincinnati, United States

Title: Suppression of Breast Cancer by Small Molecules That Block the Prolactin Receptor

Excited to feature groundbreaking work on small molecule inhibitors (SMIs) that target the prolactin receptor (PRLR)—a key driver of breast cancer growth, invasion, and chemotherapy resistance.

Highlights from this pre-clinical research include:
✨ High-throughput screening of 51,000 molecules, leading to two promising candidates—SMI-1 and SMI-6
✨ Both molecules bind the PRLR with strong affinity (1–3 μM)
✨ SMI-6 shows exceptional selectivity, high anti-tumor activity, and no detectable toxicity
✨ Rapid suppression of tumor growth in mouse xenograft models
✨ Ability to block PRL-driven JAK2/STAT5 activation and inhibit cancer cell proliferation & invasion

With oral delivery, potential brain penetration, and low production costs, SMI-6 represents an exciting step toward developing a novel, targeted breast cancer therapy.

Honored to feature the work of Subhash C. Kundu (I3Bs – University of Minho, Portugal) on 3D in vitro cancer models using natural biomaterials.

Speaker: Subhash C. Kundu, 3Bs Research Group, I3Bs – University of Minho, Portugal

Title: 3D In Vitro Cancer Models Using Natural Biomaterials for Studying the Tumor Microenvironment and Drug Screening

Excited to highlight groundbreaking work on 3D in vitro cancer models and how natural biomaterials are reshaping cancer research.
Traditional 2D cultures fall short in replicating the complexity of tumors, but 3D biomaterials—hydrogels, scaffolds, nanofibers, and bioinks—bring us closer to true physiological relevance.

🔬 Key themes from the research:
• Recreating realistic tumor microenvironments
• Studying cancer progression, invasion & drug resistance
• Using natural polymers like collagen, hyaluronic acid, alginate & silk
• Unique advantages of silk-based biomaterials: strong, tunable, biocompatible
• Enhancing predictive drug screening & reducing dependence on animal models

This work represents an important step toward more accurate cancer models, improved therapeutic evaluation, and sustainable biomedical innovation.

CANCER 2025 Day-01 In-Person talk by Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

Presentation Title: Personalized and Precision Medicine (PPM) through the Lens of Biodesign-Inspired Translational Research

Excited to share insights on how genomics-informed care is reshaping the future of oncology.

From NGS and GWAS technologies to biopredictors of pre-cancer conditions, the era of Personalized & Precision Oncology (PPO) is enabling us to detect, classify, and treat cancer at an unprecedented level of accuracy.

Key highlights:

✨ Subclinical recognition of genomic abnormalities long before symptoms emerge

✨ Identification of actionable mutations for targeted therapy

✨ Integrating genomics-driven data to improve outcomes and reduce adverse events

✨ Biodesign as a driving force for next-generation diagnostic and therapeutic tools

✨ The need for clear clinical guidelines to accelerate PPM adoption

The future of cancer care lies in collaboration between clinicians, pathologists, bioengineers, and biodesign experts—working together to transform treatment pathways and patient safety.

Groundbreaking Discovery: Small Molecules That Suppress Breast Cancer by Targeting the Prolactin Receptor

👩‍⚕️ Presented by: Dr. Nira Ben-Jonathan, University of Cincinnati, USA

📣 Presentation Type: Oral (In-Person)
Title: Suppression of breast cancer by small molecules that block the prolactin receptor

---

🔍 Revolutionizing Breast Cancer Treatment

Breast cancer continues to challenge researchers worldwide, but new insights are paving the way for innovative treatments. Dr. Nira Ben-Jonathan, an eminent cancer biologist from the University of Cincinnati, presents an exciting pre-clinical breakthrough — small molecules capable of blocking the prolactin receptor (PRLR) and halting tumor growth.

---

💡 Key Findings & Scientific Insights

• 🔸 Discovery of Novel Inhibitors: Two small molecule inhibitors, SMI-1 and SMI-6, were identified through high-throughput screening of 51,000 compounds.
• 🔸 Precise Mechanism: Both molecules effectively bind to the prolactin receptor, disrupting its role in tumor cell proliferation and invasion.
• 🔸 Powerful Selectivity: SMI-6 stands out for targeting malignant breast cancer cells while sparing normal, healthy cells.
• 🔸 Preclinical Success: In animal models, SMI-6 dramatically reduced breast cancer tumor growth with no visible toxicity.
• 🔸 Therapeutic Advantages: Oral deliverability, potential brain penetration (for metastases), and ease of optimization make SMI-6 a strong candidate for future cancer therapies.

---

🌿 Why This Study Matters

Prolactin, a hormone produced in both the pituitary and other tissues, has been known to promote cancer growth. By blocking its receptor, Dr. Ben-Jonathan’s team introduces a new strategy to prevent tumor progression and enhance treatment selectivity — marking a significant step toward targeted, non-toxic cancer therapies.

---

👩‍🔬 About Dr. Nira Ben-Jonathan

A highly respected leader in cancer biology, Dr. Ben-Jonathan’s career is decorated with achievements:

• Authored over 180 scientific papers and 12 textbook chapters.
• Fellow of the AAAS and Royal Society of Medicine.
• Recipient of the NIH Research Career Development Award, Rieveschl Award, and Merker Lectureship in Translational Endocrinology.
• Served on multiple NIH, DOD, and Komen Foundation committees, and chaired five NIH Study Sections.

Her research continues to shape the understanding of hormonal regulation in cancer biology and inspire future generations of scientists.

---

🌏 Join the Global Cancer Science Community

Be part of the International Conference on Cancer Science and Research (ICCSR 2025) — a hybrid event uniting global experts to discuss breakthroughs in cancer prevention, diagnosis, and therapy.

🎓 Event: International Conference on Cancer Science and Research
📅 November 17–19, 2025 | 📍 Singapore & Online
🔗 Visit Official Website

👉 Register Now: https://cancer.miconferences.com/register
🧬 Submit Your Abstract: https://cancer.miconferences.com/abstract-submission
📧 Email: cancer@mathewsconference.com | 📞 +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🐦 Follow on X: @CancerWorldConf

---

#BreastCancerResearch #CancerScience2025 #ProlactinReceptor #CancerTherapy #SMI6 #OncologyInnovation #CancerConference #SingaporeConference #CancerAwareness #DrugDiscovery #CancerBiology #MathewsConferences #CancerTreatment #OncologyResearch #BreastCancerAwareness

New Hope Against Oral Cancer: Thienopyrimidines Show Strong Selectivity in Targeting Tumor Cells

Oral cancer continues to be a major health challenge worldwide, with oral squamous cell carcinoma (OSCC) ranking among the most aggressive and difficult-to-treat cancers of the head and neck. A new study by Prof. Biliana Nikolova and her research team at the Bulgarian Academy of Sciences has introduced a promising direction in selective cancer therapy using thienopyrimidine-based compounds.

Title: Targeting oral squamous cell carcinoma with thienopyrimidines

🧬 Research Insight

The research explored seven novel 2-substituted 4-amino-thieno[2,3-d]pyrimidines—originally designed as DPP-4 inhibitors—for their cytotoxic and selective effects against oral cancer cells. Tests were performed on SCC-9 and HSC-3 cell lines, along with normal HaCaT keratinocytes to evaluate compound safety and specificity.

🌟 Major Findings

• Compound 6 stood out with the highest selectivity index (SI = 22.3 for SCC-9 and SI = 6.4 for HSC-3), showing strong anticancer potential.
• Compound 4 also displayed impressive selectivity (SI = 12.8), while compound 5 performed comparably to doxorubicin.
• Advanced biophysical analyses, including FACS, colony-forming, and cell migration assays, confirmed their ability to inhibit cancer cell growth and spread.
• The study highlights compound 6 as a lead candidate for further development as a selective oral cancer therapeutic with reduced side effects on normal cells.

👩‍🔬 About the Scientist

Prof. Biliana Nikolova is a distinguished biophysicist specializing in the impact of electric fields and nanomedicine applications in cancer therapy. At the Institute of Biophysics and Biomedical Engineering, she leads pioneering research that bridges biophysics, electrotherapy, and biomedical engineering. Her work continues to inspire new strategies in targeted cancer treatment and tissue regeneration.

🌍 Presented At

🧫 International Conference on Cancer Science and Research
📅 November 17–19, 2025 | Singapore & Online
🌐 https://cancer.miconferences.com/

---

#OralCancerResearch #CancerScience #Biophysics #Thienopyrimidines #CancerInnovation #CancerTherapy #BiomedicalResearch #OSCC #CancerWorldConf #Cancer2025 #OncologyUpdates #CancerConferenceSingapore